Early Statins After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk

Dementia Risk and Statin Timing in Type 2 Diabetes

As the global population ages, the burden of dementia is projected to rise, making prevention an urgent priority. According to data cited from the Lancet Commission by presenter Dr. Tummas Ternhamar from Copenhagen University Hospital, nearly half of all dementia cases can theoretically be prevented by eliminating 14 specific risk factors. Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) starting in midlife is one of those key prevention targets.

This approach holds particular clinical relevance for patients diagnosed with type 2 diabetes, because elevated LDL-C occurs frequently in this population, and diabetes itself serves as a highlighted risk factor for cognitive decline and dementia. To investigate whether lowering cholesterol early protects cognitive health, researchers utilized Danish national registers to identify 132,585 statin-naïve individuals who developed type 2 diabetes between 2006 and 2019, tracking their health outcomes through the end of 2021.

Study Design and Findings Over a Decade

The research team employed a clone-censor-weight study design—an analytical method intended to emulate a randomized trial and minimize biases common in observational research—to evaluate all-cause dementia diagnoses across three distinct treatment windows. Patients were categorized by whether they initiated statins within one year of diagnosis (early initiation), between one and five years after diagnosis (late initiation), or received no statins within the first five years.

During a median follow-up period of 7.1 years, 2.7% of the study participants developed dementia. Over a 10-year period, early statin treatment yielded a 15% lower relative risk of dementia compared to no statin initiation. Late statin initiation, meanwhile, was associated with a 10% lower relative risk over the same timeframe. Dr. Ternhamar noted that these protective associations appeared similar in both women and men.

Clinical Implications and Study Limitations

While statins are widely prescribed to reduce the risk of heart attacks and strokes in patients with type 2 diabetes, Dr. Ternhamar stated that the medications appear underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease. The findings point to an additional potentially important reason for ensuring timely lipid-lowering treatment following a diabetes diagnosis.

Commenting on the findings, Professor Isabel Goncalves, Member of the ESC Communication Committee, emphasized that because the research was observational, it cannot definitively prove that statins prevent dementia. Instead, Professor Goncalves suggested the results should encourage further investigation and serve as a practical foundation for discussions between patients and clinicians regarding comprehensive long-term health management.